Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines

Clinical and Experimental Metastasis

Volumn 31, Issue 7, 2014, Pages 771-786

  Marino, Natascia ^a   Collins, Joshua W ^a   Shen, Changyu ^b   Caplen, Natasha J ^a   Merchant, Anand S ^c   Gökmen Polar, Yesim ^b   Goswami, Chirayu P ^b   Hoshino, Takashi ^d   Qian, Yongzhen ^e   Sledge, George W ^b,f   Steeg, Patricia S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^e SAIC FREDERICK INC   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bioinformatics; Breast cancer; Gene expression profiling; Metastasis; Metastasis suppressor genes; PDE5A

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; 2',5' OLIGOADENYLATE SYNTHETASE 1; BREAST CANCER ANTI ESTROGEN RESISTANCE 4; CARBONATE DEHYDRATASE IX; CASPASE 8; CD82 ANTIGEN; CHEMOKINE RECEPTOR CXCR7; CONTACTIN ASSOCIATED PROTEIN LIKE 4; CYTOCHROME P450 4V2; DYNAMIN III; GAMMA SECRETASE; GAMMA SECRETASE APH 1B; GLUCURONOSYLTRANSFERASE; HERMES ANTIGEN; INTERLEUKIN 11 RECEPTOR ALPHA; LEUPAXIN; MATRIX METALLOPROTEINASE 16; METASTIN; NUCLEAR RECEPTOR INTERACTING PROTEIN 3; PHOSPHODIESTERASE V; SMALL INTERFERING RNA; THIOREDOXIN REDUCTASE 1; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; IN VITRO STUDY; LUNG METASTASIS; MCF 7 CELL LINE; METASTASIS SUPPRESSOR GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; SUPPRESSOR GENE; UPREGULATION; ANIMAL; BREAST TUMOR; GENETICS; HUMAN; METASTASIS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VALIDATION STUDY;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICE; NEOPLASM METASTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84911005307     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-014-9667-0     Document Type: Article

References (90)

1. DeSantis C et al (2014) Breast cancer statistics, 2013. CA Cancer J Clin 64(1):52–62
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30
3. Eccles SA, Welch DR (2007) Metastasis: recent discoveries and novel treatment strategies. Lancet 369(9574):1742–1757
4. Stafford LJ, Vaidya KS, Welch DR (2008) Metastasis suppressors genes in cancer. Int J Biochem Cell Biol 40(5):874–891
5. Steeg PS et al (1988) Altered expression of NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis. Cancer Res 48(22):6550–6554
6. Sleeman J, Steeg PS (2010) Cancer metastasis as a therapeutic target. Eur J Cancer 46(7):1177–1180
7. Berger JC et al (2005) Metastasis suppressor genes: from gene identification to protein function and regulation. Cancer Biol Ther 4(8):805–812
8. Samant RS et al (2007) Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer 6:6
9. Smith SC, Theodorescu D (2009) Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer 9(4):253–264
10. Palmieri D et al (2005) Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst 97(9):632–642
11. Liu F, Qi HL, Chen HL (2000) Effects of all-trans retinoic acid and epidermal growth factor on the expression of Nm23-H1 in human hepatocarcinoma cells. J Cancer Res Clin Oncol 126(2):85–90
12. Mashimo T et al (2000) Activation of the tumor metastasis suppressor gene, KAI1, by etoposide is mediated by p53 and c-Jun genes. Biochem Biophys Res Commun 274(2):370–376
13. El Touny LH, Banerjee PP (2007) Genistein induces the metastasis suppressor kangai-1 which mediates its anti-invasive effects in TRAMP cancer cells. Biochem Biophys Res Commun 361(1):169–175
14. Horak CE et al (2007) Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. Cancer Res 67(24):11751–11759
15. Titus B et al (2005) Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 65(16):7320–7327
16. Horak CE et al (2007) Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2. Cancer Res 67(15):7238–7246
17. Marshall JC et al (2012) Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J Natl Cancer Inst 104(17):1306–1319
18. Minn AJ et al (2012) Identification of novel metastasis suppressor signaling pathways for breast cancer. Cell Cycle 11(13):2452–2457
19. Yun J et al (2011) Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO J 30(21):4500–4514
20. Xia W et al (2001) The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res 61(14):5644–5651
21. Theodorescu D et al (2004) Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 10(11):3800–3806
22. Phadke PA et al (2008) BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. Am J Pathol 172(3):809–817
23. Stupack DG et al (2006) Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439(7072):95–99
24. Rudy W et al (1993) The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res 53(6):1262–1268
25. Kallakury BV et al (1996) Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Cancer 78(7):1461–1469
26. Phillips KK et al (1998) Correlation between reduction of metastasis in the MDA-MB-435 model system and increased expression of the Kai-1 protein. Mol Carcinog 21(2):111–120
27. Yang X et al (1997) KAI1, a putative marker for metastatic potential in human breast cancer. Cancer Lett 119(2):149–155
28. Perl AK et al (1998) A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392(6672):190–193
29. Frixen UH et al (1991) E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113(1):173–185
30. Kashima T et al (2003) Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer (Journal international du cancer) 104(2):147–154
31. Nakajima G et al (2008) CDH11 expression is associated with survival in patients with osteosarcoma. Cancer Genomics Proteomics 5(1):37–42
32. Guan RJ et al (2000) Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res 60(3):749–755
33. Fujita H et al (2001) Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect. Int J Cancer (Journal international du cancer) 93(6):773–780
34. Beck BH, Welch DR (2010) The KISS1 metastasis suppressor: a good night kiss for disseminated cancer cells. Eur J Cancer 46(7):1283–1289
35. Yamada SD et al (2002) Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res 62(22):6717–6723
36. Hickson JA et al (2006) The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res 66(4):2264–2270
37. Vander Griend DJ et al (2005) Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res 65(23):10984–10991
38. Hagan S et al (2005) Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Re 11(20):7392–7397
39. Gautam A, Bepler G (2006) Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res 66(13):6497–6502
40. Beyer I et al (2011) Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. Mol Ther 19(3):479–489
41. Wang Y et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460):671–679
42. Pawitan Y et al (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res: BCR 7(6):R953–R964
43. Muggerud AA et al (2010) Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol 4(4):357–368
44. Guillemette C et al (2010) UGT genomic diversity: beyond gene duplication. Drug Metab Rev 42(1):24–44
45. Guillemette C et al (2000) Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 60(4):950–956
46. Albert C et al (1999) The monkey and human uridine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes. Endocrinology 140(7):3292–3302
47. Okamoto PM, Herskovits JS, Vallee RB (1997) Role of the basic, proline-rich region of dynamin in Src homology 3 domain binding and endocytosis. J Biol Chem 272(17):11629–11635
48. Justesen J, Hartmann R, Kjeldgaard NO (2000) Gene structure and function of the 2′-5′-oligoadenylate synthetase family. Cell Mol Life Sci: CMLS 57(11):1593–1612
49. Taga T, Kishimoto T (1997) Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15:797–819
50. Juilfs DM et al (1999) Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev Physiol Biochem Pharmacol 135:67–104
51. Boolell M et al (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8(2):47–52
52. Weber GF (2013) Why does cancer therapy lack effective anti-metastasis drugs? Cancer Lett 328(2):207–211
53. Brabletz T et al (2013) Roadblocks to translational advances on metastasis research. Nat Med 19(9):1104–1109
54. Steeg PS (2012) Perspective: the right trials. Nature 485(7400):S58–S59
55. Perrais D, Merrifield CJ (2005) Dynamics of endocytic vesicle creation. Dev Cell 9(5):581–592
56. Ochoa GC et al (2000) A functional link between dynamin and the actin cytoskeleton at podosomes. J Cell Biol 150(2):377–389
57. Gold ES et al (1999) Dynamin 2 is required for phagocytosis in macrophages. J Exp Med 190(12):1849–1856
58. Kruchten AE, McNiven MA (2006) Dynamin as a mover and pincher during cell migration and invasion. J Cell Sci 119(Pt 9):1683–1690
59. Thompson HM et al (2002) The large GTPase dynamin associates with the spindle midzone and is required for cytokinesis. Curr Biol: CB 12(24):2111–2117
60. Harper CB et al (2013) Targeting membrane trafficking in infection prophylaxis: dynamin inhibitors. Trends Cell Biol 23(2):90–101
61. Domingo-Gil E, Esteban M (2006) Role of mitochondria in apoptosis induced by the 2-5A system and mechanisms involved. Apoptosis: Int J Program Cell Death 11(5):725–738
62. Mandal S, Abebe F, Chaudhary J (2011) 2′-5′ Oligoadenylate synthetase 1 polymorphism is associated with prostate cancer. Cancer 117(24):5509–5518
63. Kazma R et al (2012) Association of the innate immunity and inflammation pathway with advanced prostate cancer risk. PLoS One 7(12):e51680
64. Campbell CL et al (2001) Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am J Pathol 158(1):25–32
65. Campbell CL et al (2001) Interleukin-11 receptor expression in primary ovarian carcinomas. Gynecol Oncol 80(2):121–127
66. Hanavadi S et al (2006) Expression of interleukin 11 and its receptor and their prognostic value in human breast cancer. Ann Surg Oncol 13(6):802–808
67. Yoshizaki A et al (2006) Expression of interleukin (IL)-11 and IL-11 receptor in human colorectal adenocarcinoma: IL-11 up-regulation of the invasive and proliferative activity of human colorectal carcinoma cells. Int J Oncol 29(4):869–876
68. Mackenzie PI et al (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15(10):677–685
69. Gong QH et al (2001) Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11(4):357–368
70. Lepine J et al (2004) Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab 89(10):5222–5232
71. Gagne JF et al (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62(3):608–617
72. Innocenti F et al (2005) Haplotypes of variants in the UDP-glucuronosyltransferase 1A9 and 1A1 genes. Pharmacogenet Genomics 15(5):295–301
73. Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109(3):366–398
74. Maurice DH et al (2014) Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 13(4):290–314
75. Lim JT et al (1999) Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 58(7):1097–1107
76. Sarfati M et al (2003) Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 101(1):265–269
77. Zhu B et al (2005) Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 94(2):336–350
78. Shimizu-Albergine M et al (2003) Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation. J Neurosci 23(16):6452–6459
79. Li Z et al (2003) A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell 112(1):77–86
80. Sopory S, Kaur T, Visweswariah SS (2004) The cGMP-binding, cGMP-specific phosphodiesterase (PDE5): intestinal cell expression, regulation and role in fluid secretion. Cell Signal 16(6):681–692
81. Stark S et al (2001) Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 40(2):181–188 discussion 9–90
82. Yip-Schneider MT et al (2001) Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 298(3):976–985
83. Pusztai L et al (2003) Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 21(18):3454–3461
84. Whitehead CM et al (2003) Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther 2(5):479–488
85. Soriano AF et al (1999) Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59(24):6178–6184
86. Li Q, Shu Y (2014) Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cells. Pharm Res 31(1):86–96. doi:10.1007/s11095-013-1134-0
87. Hu J et al (2010) Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS One 5(4):e10108
88. Arozarena I et al (2011) Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 19(1):45–57
89. Murthy KS (2008) Contractile agonists attenuate cGMP levels by stimulating phosphorylation of cGMP-specific PDE5; an effect mediated by RhoA/PKC-dependent inhibition of protein phosphatase 1. Br J Pharmacol 153(6):1214–1224
90. Geng Y et al (1998) Cyclic GMP and cGMP-binding phosphodiesterase are required for interleukin-1-induced nitric oxide synthesis in human articular chondrocytes. J Biol Chem 273(42):27484–27491